Gynoflor

Gynoflor is a vaginal tablet that combines the estrogenic hormone estriol with lyophilized Lactobacillus acidophilus. The formulation is designed for local application in the vagina to address estrogen deficiency‑related conditions. As a prescription‑only product marketed in the European Union, Gynoflor delivers both hormonal and probiotic actions to support vaginal tissue health and restore a balanced microbiome. It is intended for adult women experiencing menopausal or post‑menopausal changes.

Gynoflor is prescribed for several gynecological conditions linked to low estrogen levels in the vaginal environment, providing both hormonal and probiotic actions to improve tissue health and microbial balance.

- Treatment of vaginal atrophy caused by estrogen deficiency. - Relief of dyspareunia (painful intercourse) associated with vaginal dryness. - Management of vulvovaginal dryness and irritation in postmenopausal women. - Support of the normal vaginal flora after antibiotic or antifungal therapy. - Adjunct therapy for women using systemic hormone replacement who need local symptom control.

The safety profile of Gynoflor reflects the local nature of the product, with most adverse events being mild and transient.

Common: - Vaginal irritation or mild burning sensation. - Spotting or light vaginal bleeding. - Increased vaginal discharge that is clear or whitish. - Mild abdominal cramping.

Serious: - Allergic reaction such as rash, itching, or swelling of the genital area. - Severe vaginal bleeding or hemorrhage. - Signs of estrogen excess, including breast tenderness or swelling. - Thromboembolic events (rare but reported with systemic estrogen exposure).

Before initiating Gynoflor, healthcare providers should evaluate patient history and consider specific contraindications and risk factors.

- Not recommended for women with known hypersensitivity to estriol or Lactobacillus acidophilus. - Caution in patients with a history of estrogen‑dependent neoplasms (e.g., breast or endometrial cancer). - Use carefully in individuals with unexplained vaginal bleeding; investigate the cause before treatment. - Avoid in women with active thromboembolic disorders or severe liver disease. - Discuss potential risks with pregnant or breastfeeding women, as safety data are limited. - Monitor for signs of vaginal infection or irritation during therapy.

Gynoflor may interact with other medications or products that influence estrogen activity or vaginal flora.

Avoid: - Systemic estrogen therapy (e.g., oral estradiol) without medical supervision, which may increase estrogen exposure. - Antifungal or antibacterial vaginal preparations used concurrently, which could alter probiotic effectiveness.

Use with caution: - Hormonal contraceptives containing estrogen, requiring dose adjustment. - Selective estrogen receptor modulators (SERMs) such as tamoxifen. - Medications that increase the risk of thrombosis (e.g., oral anticoagulants). - Herbal supplements with estrogenic properties (e.g., black cohosh, phytoestrogens).